← Back to Search

Not Applicable

Apollo System for ADHD

N/A
Waitlist Available
Led By Matthew B Pontifex, PhD.
Research Sponsored by Michigan State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must be 8 years of age or older and under the age of 18
Participants must have diagnosed or suspected Attention Deficit Hyperactivity Disorder (ADHD)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up prior to and following the 8 week study protocol period.

Summary

This trial is testing the Apollo System, a device that uses vibrations to help balance the body's nervous system. It is aimed at children with ADHD to see if it can help them focus and control their behavior better. The study will compare the effects of the device.

Who is the study for?
This trial is for children aged 8-18 with ADHD who have had minimal relief from current treatments, tried multiple treatments without meeting goals, still experience symptoms on medication, or suffer from medication side effects. It's open to all genders and ethnicities.
What is being tested?
The Apollo System is being tested over an 8-week period at home to see if it can reduce ADHD symptoms in children who meet the study criteria.
What are the potential side effects?
The information provided does not specify side effects of the Apollo System. Typically, clinical trials monitor participants for any adverse reactions during the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 8 and 17 years old.
Select...
I have been diagnosed with or suspected to have ADHD.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~prior to and following the 8 week study protocol period.
This trial's timeline: 3 weeks for screening, Varies for treatment, and prior to and following the 8 week study protocol period. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in ADHD symptomatology as assessed using the ADHD-5 Rating Scale
Effect Size for Change in Behavioral Index of Interference Control
Effect Size for Change in Behavioral Index of Response Inhibition

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Commercial Apollo System DeviceExperimental Treatment1 Intervention
The active experimental group received the commercial Apollo System device.
Group II: Sham Apollo System DevicePlacebo Group1 Intervention
The control experimental group received a sham/placebo device that is identical to the commercial Apollo System device but uses an ultra-low (i.e., effectively zero) frequency pattern of vibrations.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for ADHD are stimulant medications such as methylphenidate and amphetamines, which work by increasing the levels of dopamine and norepinephrine in the brain, thereby enhancing attention and reducing hyperactive and impulsive behaviors. Non-stimulant medications like atomoxetine increase norepinephrine levels by inhibiting its reuptake. These mechanisms are crucial for ADHD patients as they help to normalize brain activity associated with attention and behavior control. The Apollo System, a wearable device delivering gentle vibrations to influence the autonomic nervous system, represents a novel approach by potentially modulating stress and improving focus through non-pharmacological means.
Enhancing attention in neurodegenerative diseases: current therapies and future directions.Attention-deficit/hyperactivity disorder and complementary/alternative medicine.

Find a Location

Who is running the clinical trial?

The Board of MedicineUNKNOWN
3 Previous Clinical Trials
700 Total Patients Enrolled
Michigan State UniversityLead Sponsor
198 Previous Clinical Trials
685,634 Total Patients Enrolled
Matthew B Pontifex, PhD.Principal InvestigatorMichigan State University

Media Library

Apollo System (Not Applicable) Clinical Trial Eligibility Overview. Trial Name: NCT05308706 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: Commercial Apollo System Device, Sham Apollo System Device
Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: Apollo System Highlights & Side Effects. Trial Name: NCT05308706 — N/A
Apollo System (Not Applicable) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05308706 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Patient Testimony for trial: Trial Name: NCT05308706 — N/A
~27 spots leftby Dec 2025